MedTrace Logo

Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Post COVID-19

NCT06940765 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2025-04-23

No results posted yet for this study

Summary

This study is an early feasibility study to evaluate the safety of a single intravenous injection of autologous adipose-derived SVF produced using the GID SVF-2 device system for treatment of continuing respiratory distress after recovery from COVID-19.

Conditions

  • Covid19

Interventions

DEVICE

GID SVF-2 Device System

The GID SVF-2 device is indicated for use for harvesting, filtering, separating, and concentrating autologous stromal vascular fraction cells from adipose tissue.

Sponsors & Collaborators

  • GID BIO, Inc.

    lead INDUSTRY

Principal Investigators

  • William Cimino, Phd · GID BIO

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2022-05-31
Completion
2022-05-31
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06940765 on ClinicalTrials.gov